Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 657

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 657
---
 with other related party: Cibic Since inception the Company commercializes its Diagnostics services through an exclusive commercialization agreement with CIBIC, one of the shareholders of Heritas Ltd, the parent company of the Company.

|                   |     |        As of 
 December 31, 
         2024 |     |    As of 
 June 30, 
     2024 |
|:------------------|:----|-------------:|:----|---------:|
| Trade receivables |     |      248,504 |     |   18,056 |
| Trade payables    |     |       12,864 |     |   21,024 |

F-113

Notes to Unaudited Interim Condensed Combined Financial Statements (Amounts in US Dollars, except otherwise indicated) 20.Related parties (cont.) Transactions with CIBIC are as follows:

|                                       |     | For the six-month period ended 
                   December 31, 
                           2024 |     |    2023 |
|:--------------------------------------|:----|-------------------------------:|:----|--------:|
| Revenue                               |     |                        682,147 |     | 645,496 |
| Laboratory services provided by CIBIC |     |                         16,764 |     |       — |
| IT services provided by CIBIC         |     |                          9,204 |     |  10,792 |

Indear

|                      |     | For the six-month period ended 
 December 31,                   
 2024                           |     |   2023 |
|:---------------------|:----|:-------------------------------|:----|-------:|
| Purchase of services |     | —                              |     | 38,210 |

Bioceres

|                             |     |        As of 
 December 31, 
         2024 |     |    As of 
 June 30, 
     2024 |
|:----------------------------|:----|-------------:|:----|---------:|
| Trade and other receivables |     |        2,690 |     |    3,536 |

The following transactions occurred with Bioceres:

|         |     | For the six-month period ended 
 December 31,                   
 2024                           |     |  2023 |
|:--------|:----|:-------------------------------|:----|------:|
| Revenue |     | —                              |     |